Obatoclax Mesylate (GX15-070)

Name: Obatoclax Mesylate (GX15-070)
Brand: Selleck Chemicals
SKU: S1057
Rating: 5 (74 reviews)

For research use only.

Catalog No.S1057

74 publications

Obatoclax Mesylate (GX15-070) Chemical Structure

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Selleck's Obatoclax Mesylate (GX15-070) has been cited by 74 publications

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(6)

PubMed: 30875757 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563080 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):965

PubMed: 30305055 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472.CAN-16-3424

PubMed: ( click the link to review the publication )

Genome Med, 2017, 9(1):40

PubMed: 28446242 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):52

PubMed: 28403890 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

FEBS J, 2017, 284(2):222-236

PubMed: 27860276 ( click the link to review the publication )

Antimicrob Agents Chemother, 2017, 61(3)

PubMed: 27993855 ( click the link to review the publication )

Electrophoresis, 2017, 10.1002/elps.201600447

PubMed: 28608427 ( click the link to review the publication )

J Exp Med, 2017, 214(6):1691-1710

PubMed: 28450382 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664 ( click the link to review the publication )
Antiviral Res, 2016, 126:69-80

PubMed: 26738783 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56253-56265

PubMed: 27494845 ( click the link to review the publication )

Oncotarget, 2016, 8(36):60060-60079

PubMed: 28947954 ( click the link to review the publication )

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e2014

PubMed: 26658189 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2015, 15:97

PubMed: 26464561 ( click the link to review the publication )

Int J Oncol, 2015, 46(4):1844-8

PubMed: 25647738 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Mol Cells, 2015, 38(3):279-84

PubMed: 25666350 ( click the link to review the publication )

Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

J Pharm Pharmacol, 2015, 67(11):1575-84

PubMed: 26255619 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):755-67

PubMed: 25012986 ( click the link to review the publication )

Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266 ( click the link to review the publication )
Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809 ( click the link to review the publication )

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2789-94

PubMed: 25333301 ( click the link to review the publication )

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

Genes Cancer, 2014, 5(11-12):445-59

PubMed: 25568669 ( click the link to review the publication )

Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/ ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(4):448-59

PubMed: 23395885 ( click the link to review the publication )

J Immunol, 2013, 190(9):4621-6

PubMed: 23547112 ( click the link to review the publication )

Apoptosis, 2013, 18(10):1163-74

PubMed: 23887890 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 49(4):609-18

PubMed: 23668615 ( click the link to review the publication )

Exp Cell Res, 2013, 319(10):1443-50

PubMed: 23416067 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55982

PubMed: 23418490 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e299

PubMed: 22513873 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )
Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

BMC Cancer, 2011, 11:24

PubMed: 21247487 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	NFqydI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMECwNFMyPyEQvF2=	M3LCW3NCVkeHUh?=
SK-MEL-30	NGXkOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HMZmlEPTB;MD6wNFA{PTVizszN	MlrDV2FPT0WU
NALM-6	NYTle3pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwMECwN\|U3KM7:TR?=	NEnHNIxUSU6JRWK=
KYSE-450	NHrGfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O0eWlEPTB;MD6wNFA1PjlizszN	NH7se2lUSU6JRWK=
BHY	M4mxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HKc2lEPTB;MD6wNFA3ODFizszN	NEftNVNUSU6JRWK=
GR-ST	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTzc5hDUUN3ME2wMlAxODZ2ODFOwG0>	NEDpNVNUSU6JRWK=
786-0	M1HZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwMECwO\|c3KM7:TR?=	M12zWnNCVkeHUh?=
C-33-A	MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfsbnhKSzVyPUCuNFAxQDR6IN88US=>	MVHTRW5ITVJ?
BHT-101	NUfkT5czT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfGPY9RUUN3ME2wMlAxOTB4IN88US=>	MYrTRW5ITVJ?
EB2	NEnIOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH20cIdKSzVyPUCuNFAyOThizszN	M1zGfXNCVkeHUh?=
G-361	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\1VWlEPTB;MD6wNFEzPCEQvF2=	MlPOV2FPT0WU
KE-37	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLEXFBKSzVyPUCuNFAyOjhizszN	NF\2OHpUSU6JRWK=
MHH-PREB-1	M4q1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUH1eZV{UUN3ME2wMlAxOTRizszN	NWDNNnpKW0GQR1XS
MCF7	NEPQXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\UVoRwUUN3ME2wMlAxOTV7IN88US=>	NFjse3JUSU6JRWK=
LOUCY	Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWG2cHdrUUN3ME2wMlAxOTd3IN88US=>	NFi0NmpUSU6JRWK=
EW-7	NIDKdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMECxO\|Uh\|ryP	M2TXb3NCVkeHUh?=
KYSE-510	M4PVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMECyN\|Mh\|ryP	NE\yU\|hUSU6JRWK=
SK-MEL-3	NXiwb5pRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfrTWM2OD1yLkCwNlY1KM7:TR?=	M{L1XnNCVkeHUh?=
HAL-01	MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwMECyPVch\|ryP	MXrTRW5ITVJ?
HCC2998	M3fuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMECzN\|Uh\|ryP	MV;TRW5ITVJ?
A375	M2DjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUflTWc5UUN3ME2wMlAxOzVizszN	NHLsUFZUSU6JRWK=
MZ7-mel	NGTQSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Kx[2lEPTB;MD6wNFM6QSEQvF2=	MY\TRW5ITVJ?
SH-4	M1fkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWi3NWNUUUN3ME2wMlAxPDF5IN88US=>	NGPyWZhUSU6JRWK=
HT-144	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PaSWlEPTB;MD6wNFQ{KM7:TR?=	NH;FNlJUSU6JRWK=
KYSE-140	NIrXZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlKzTWM2OD1yLkCwOFM2KM7:TR?=	NIXIfWVUSU6JRWK=
PSN1	NHnYOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LtNGlEPTB;MD6wNFQ3PyEQvF2=	NGjsXGdUSU6JRWK=
COLO-679	NILneFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXtfGFKSzVyPUCuNFA1QThizszN	NFKxcFBUSU6JRWK=
SW620	NGPR[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknuTWM2OD1yLkCwOVEyKM7:TR?=	Ml7hV2FPT0WU
HGC-27	NVTFdm1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIS0dm9KSzVyPUCuNFA2OjRizszN	MWTTRW5ITVJ?
IGROV-1	NHToOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjHR3FrUUN3ME2wMlAxPiEQvF2=	NVfPTpp5W0GQR1XS
IGR-1	NIj5U2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMEC2NFEh\|ryP	MWjTRW5ITVJ?
EW-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\TTWM2OD1yLkCwOlUyKM7:TR?=	NGLQdVFUSU6JRWK=
769-P	MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF:2d2NKSzVyPUCuNFA3PzhizszN	M1\TSHNCVkeHUh?=
HN	NFTkfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jzOGlEPTB;MD6wNFY4QSEQvF2=	NWTzWHR1W0GQR1XS
SIG-M5	NGjwWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILZc45KSzVyPUCuNFA4OSEQvF2=	MVnTRW5ITVJ?
IST-MEL1	NYjMZlByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzRfJVKSzVyPUCuNFA5OThizszN	MWXTRW5ITVJ?
ST486	NYDXcHZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDDXHZ6UUN3ME2wMlAxQDJ3IN88US=>	NXXwXmNSW0GQR1XS
ES7	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPkNI9KSzVyPUCuNFA5PDZizszN	NUjxUmFXW0GQR1XS
GAK	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnPXWFKSzVyPUCuNFA5PDhizszN	NGP1eXVUSU6JRWK=
BB30-HNC	M4PTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\xPWlEPTB;MD6wNFg2QCEQvF2=	MYHTRW5ITVJ?
IPC-298	NUXMV\|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzacWxKSzVyPUCuNFA6OjdizszN	M4LQVHNCVkeHUh?=
NKM-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1X6emlEPTB;MD6wNFk4OiEQvF2=	MkjBV2FPT0WU
RKO	MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M32zbmlEPTB;MD6wNVA1PCEQvF2=	MknSV2FPT0WU
ACN	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfx[XIzUUN3ME2wMlAyOTNzIN88US=>	M1ywd3NCVkeHUh?=
SW1417	NYfPVmR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEmzS4FKSzVyPUCuNFEzOjVizszN	NGfPPFBUSU6JRWK=
SR	NFj1dY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnZR3pKSzVyPUCuNFEzOzVizszN	NEK0N3BUSU6JRWK=
SNG-M	NHnY[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLWTXJEUUN3ME2wMlAyOzF5IN88US=>	M1zvd3NCVkeHUh?=
CAL-12T	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zaOGlEPTB;MD6wNVM1PiEQvF2=	M2ntdHNCVkeHUh?=
HSC-3	MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHmemo4UUN3ME2wMlAyOzV3IN88US=>	MYTTRW5ITVJ?
DOHH-2	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXOfow1UUN3ME2wMlAyPDF{IN88US=>	M3XEVHNCVkeHUh?=
NB69	NXfCTnRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;zTWM2OD1yLkCxOVY2KM7:TR?=	M2DUbXNCVkeHUh?=
LC-2-ad	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;DTWM2OD1yLkCxOVgyKM7:TR?=	MVHTRW5ITVJ?
RVH-421	NFLjRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{SzeGlEPTB;MD6wNVY4PCEQvF2=	MWTTRW5ITVJ?
TGW	NEPxOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjOW4dKSzVyPUCuNFE4OzlizszN	MlvGV2FPT0WU
HCC1569	M4jPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2r0WGlEPTB;MD6wNVc6PyEQvF2=	NGLucHFUSU6JRWK=
CAL-85-1	NWThbHZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nueWlEPTB;MD6wNVg{OiEQvF2=	MmjnV2FPT0WU
RPMI-8402	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLOfFdKSzVyPUCuNFE5PThizszN	NYDydm84W0GQR1XS
THP-1	M4rIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{f3[mlEPTB;MD6wNVk6QCEQvF2=	MmL3V2FPT0WU
ONS-76	M4PaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXryPJg4UUN3ME2wMlAzODN4IN88US=>	Ml6xV2FPT0WU
A2780	Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo[2TWM2OD1yLkCyNFc6KM7:TR?=	NXjF[HA3W0GQR1XS
RPMI-2650	M{LuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7EUVhbUUN3ME2wMlAzOjl4IN88US=>	MVLTRW5ITVJ?
MEL-HO	NIC3U3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMEKzOFgh\|ryP	M1vRT3NCVkeHUh?=
MC-CAR	NFnMO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;DcpFKSzVyPUCuNFI{PTZizszN	M2f5U3NCVkeHUh?=
HSC-2	NWPtZ3MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXVVGZKSzVyPUCuNFI1PjZizszN	M3j4R3NCVkeHUh?=
MEL-JUSO	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTmd4JpUUN3ME2wMlAzPDd\|IN88US=>	MYrTRW5ITVJ?
CAL-62	NUfFeIQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33KXmlEPTB;MD6wNlYxOiEQvF2=	MkDZV2FPT0WU
DMS-273	M3e4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\PTWM2OD1yLkCyPFQ4KM7:TR?=	NIe2UWVUSU6JRWK=
S-117	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMEK5NFYh\|ryP	M1jaeHNCVkeHUh?=
SUP-T1	NGPpV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwMEK5OFkh\|ryP	MXzTRW5ITVJ?
MZ2-MEL	Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\RTWM2OD1yLkCyPVU6KM7:TR?=	MYnTRW5ITVJ?
KYSE-270	MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHP5Z4tKSzVyPUCuNFI6PzZizszN	NIfLRVdUSU6JRWK=
CMK	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLwTWM2OD1yLkCzNFI{KM7:TR?=	M4[5c3NCVkeHUh?=
8505C	NIPLZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMEOwOEDPxE1?	MX\TRW5ITVJ?
NUGC-3	NX7WT\|MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrmbYZbUUN3ME2wMlA{ODR6IN88US=>	MVHTRW5ITVJ?
A101D	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHqTWM2OD1yLkCzNFU2KM7:TR?=	MUXTRW5ITVJ?
G-401	NUHINYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkf0TWM2OD1yLkCzNFk{KM7:TR?=	M2HXbnNCVkeHUh?=
OVCAR-8	NYLhTpFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMEOxNFch\|ryP	MX\TRW5ITVJ?
IMR-5	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPUcFRPUUN3ME2wMlA{OjR2IN88US=>	M1i1[nNCVkeHUh?=
DoTc2-4510	NU[1R3I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPxTWM2OD1yLkCzN\|k{KM7:TR?=	NYLLd2JmW0GQR1XS
HOS	M1HBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMEO0O\|Mh\|ryP	NELzcWlUSU6JRWK=
HEC-1	Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMEO2PEDPxE1?	NFLXVVFUSU6JRWK=
SW756	NH[xO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEO4NlEh\|ryP	MkDxV2FPT0WU
NCI-H64	M4nkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\QNmlEPTB;MD6wN\|g1OiEQvF2=	M{XLR3NCVkeHUh?=
EW-16	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETRdZdKSzVyPUCuNFM6ODlizszN	M4DVSnNCVkeHUh?=
CAL-51	NGq0XYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DqVWlEPTB;MD6wOFAxPSEQvF2=	NV\JTWhmW0GQR1XS
KYSE-150	M4jV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMESwNVEh\|ryP	NX2ycVZqW0GQR1XS
SW1710	NUjQcVc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGi1cYNKSzVyPUCuNFQxOThizszN	M1zlVXNCVkeHUh?=
HuP-T4	M37rUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV2yeW1FUUN3ME2wMlA1OTF6IN88US=>	M2ryN3NCVkeHUh?=
LB373-MEL-D	MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEP4dZNKSzVyPUCuNFQzOzJizszN	NX3abnBvW0GQR1XS
EW-13	M4\UTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDLSllKSzVyPUCuNFQ1ODZizszN	MkHWV2FPT0WU
HT-29	NIGxWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnkfoRKSzVyPUCuNFQ1QSEQvF2=	MVnTRW5ITVJ?
SCC-25	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPQTWM2OD1yLkC0OFk1KM7:TR?=	M1X6[3NCVkeHUh?=
REH	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XrZmlEPTB;MD6wOFY{PSEQvF2=	MXnTRW5ITVJ?
L-363	NWfpS2dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPqTWM2OD1yLkC0Olc6KM7:TR?=	MmnNV2FPT0WU
NCI-H1770	M3jU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHjTWM2OD1yLkC0Olk4KM7:TR?=	MkPMV2FPT0WU
CHL-1	M2\vRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMES4OVch\|ryP	MYTTRW5ITVJ?
ES1	M{jVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMES4PFUh\|ryP	MX3TRW5ITVJ?
SCC-15	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zNcGlEPTB;MD6wOFkxOiEQvF2=	MV3TRW5ITVJ?
MRK-nu-1	M{C2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LTbGlEPTB;MD6wOFk{PiEQvF2=	Mn3CV2FPT0WU
PF-382	NYHWbmxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{L1WWlEPTB;MD6wOFk{QSEQvF2=	MX;TRW5ITVJ?
COLO-680N	NGjON2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDMRYlKSzVyPUCuNFUxPDdizszN	NEK0S5JUSU6JRWK=
LK-2	NGTSR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rYO2lEPTB;MD6wOVA3OyEQvF2=	MmHqV2FPT0WU
NCI-H2342	M1P5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHWeVZDUUN3ME2wMlA2OTF5IN88US=>	NHL6cGJUSU6JRWK=
HMV-II	M37mbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoKwTWM2OD1yLkC1NlM6KM7:TR?=	M{PI[HNCVkeHUh?=
PC-14	NF3RNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;jZYhKSzVyPUCuNFUzPTJizszN	MVvTRW5ITVJ?
COLO-320-HSR	NEjwXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HMNmlEPTB;MD6wOVI5QSEQvF2=	M1HHZXNCVkeHUh?=
697	MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWO3dVlUUUN3ME2wMlA2OzJ\|IN88US=>	MmXuV2FPT0WU
NEC8	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1O2VGlEPTB;MD6wOVU6KM7:TR?=	NVHiW2RZW0GQR1XS
LCLC-97TM1	M13GTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMEW1PVQh\|ryP	MY\TRW5ITVJ?
Daoy	NYntXotrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvzTWM2OD1yLkC1OlE3KM7:TR?=	NFr2ZmlUSU6JRWK=
ETK-1	MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVm3[nQ3UUN3ME2wMlA2Pjd{IN88US=>	NF3ifmhUSU6JRWK=
A388	NHH5TG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPPSZd4UUN3ME2wMlA2Pjl3IN88US=>	M{juWnNCVkeHUh?=
COLO-205	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrpVoNyUUN3ME2wMlA2PzF4IN88US=>	MW\TRW5ITVJ?
SK-PN-DW	MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXQOHFKSzVyPUCuNFU4OjlizszN	MnXnV2FPT0WU
SF268	NELre2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTyTWM2OD1yLkC1O\|U3KM7:TR?=	M3XHOnNCVkeHUh?=
OCI-AML2	M1H3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fpe2lEPTB;MD6wOVc4PyEQvF2=	M4[0UXNCVkeHUh?=
GAMG	NXr0[nFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\2cG9jUUN3ME2wMlA2QCEQvF2=	MlHlV2FPT0WU
BCPAP	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVj1Z295UUN3ME2wMlA2QDl{IN88US=>	NHPGepZUSU6JRWK=
BC-1	NXr6eGw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHS5[pRKSzVyPUCuNFYxOjJizszN	MmTKV2FPT0WU
IA-LM	M4P0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPFbJdKSzVyPUCuNFYxPTNizszN	NH7sW\|NUSU6JRWK=
NCI-H1299	M2KyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnQUotKUUN3ME2wMlA3OTNizszN	NHrtWXdUSU6JRWK=
COR-L23	M{LhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwME[xN\|Qh\|ryP	M1ToNXNCVkeHUh?=
KYSE-180	MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3TTWM2OD1yLkC2NVQzKM7:TR?=	NH\1N5JUSU6JRWK=
LOXIMVI	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;uUWlEPTB;MD6wOlE5QCEQvF2=	MULTRW5ITVJ?
BL-41	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;BTWM2OD1yLkC2NlE6KM7:TR?=	MVjTRW5ITVJ?
BL-70	NGLLRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HPfmlEPTB;MD6wOlMxOiEQvF2=	MlG3V2FPT0WU
NOS-1	NH24cmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jMNGlEPTB;MD6wOlQyOSEQvF2=	NV\nPFU4W0GQR1XS
NB13	NGnwNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfCV3djUUN3ME2wMlA3PDJzIN88US=>	Mor6V2FPT0WU
CAL-27	NYi5UGg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwME[0OlQh\|ryP	NFXMellUSU6JRWK=
CA46	NF75cZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVm4Sm17UUN3ME2wMlA3PTN5IN88US=>	NIDjXIZUSU6JRWK=
SW962	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwME[1Olkh\|ryP	MVPTRW5ITVJ?
NCI-H226	NFfRdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\sZ2ZKSzVyPUCuNFY3OzJizszN	NUXHVll7W0GQR1XS
KYSE-70	NFvCeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvROIRKSzVyPUCuNFY6PDVizszN	NYDH[Y45W0GQR1XS
Daudi	NYLXWYJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIC1Z2xKSzVyPUCuNFcxQDFizszN	MnvhV2FPT0WU
SW626	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTOWodKSzVyPUCuNFczODRizszN	M3XWXnNCVkeHUh?=
ESS-1	NY\SVppkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwMEeyOFYh\|ryP	NFfL[3JUSU6JRWK=
YT	M3LpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMEezOFUh\|ryP	NXHQRXhxW0GQR1XS
P12-ICHIKAWA	NUTRdnVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMEezOFkh\|ryP	NXHNSJlIW0GQR1XS
BxPC-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMEe0OVgh\|ryP	MWDTRW5ITVJ?
CTV-1	NYfhRVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGm5T\|RKSzVyPUCuNFc2OTdizszN	NVO1cZdPW0GQR1XS
MLMA	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml71TWM2OD1yLkC3OVM1KM7:TR?=	MVnTRW5ITVJ?
WSU-NHL	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEe1OVQh\|ryP	NYXqVpFsW0GQR1XS
CTB-1	NUPZZ5hWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfXTWM2OD1yLkC3OVg5KM7:TR?=	Mn\hV2FPT0WU
MMAC-SF	M2SwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMEe2Olgh\|ryP	MnnsV2FPT0WU
8-MG-BA	M2\a[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HVUmlEPTB;MD6wO\|gxOSEQvF2=	NHztdpZUSU6JRWK=
NCI-H358	M2rEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMEe4O\|kh\|ryP	NEnOW5VUSU6JRWK=
BFTC-905	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMEe5NFkh\|ryP	NEPQRoVUSU6JRWK=
NCI-H727	NFTz[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXPTWM2OD1yLkC4NFU{KM7:TR?=	NWK0c\|hQW0GQR1XS
CHP-212	NX;SOVF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTETWM2OD1yLkC4NFk2KM7:TR?=	MlW2V2FPT0WU
HOP-62	Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWL4ZVJjUUN3ME2wMlA5OjR3IN88US=>	NWq1UGI5W0GQR1XS
CESS	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoSxTWM2OD1yLkC4NlY6KM7:TR?=	MVjTRW5ITVJ?
HuCCT1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrYPGVKSzVyPUCuNFg{OzNizszN	NHXBNpJUSU6JRWK=
DEL	MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMEizOFch\|ryP	NUHtemF3W0GQR1XS
5637	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDid3pKUUN3ME2wMlA5OzZ5IN88US=>	NXrsbVU4W0GQR1XS
RS4-11	M2PpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnWUpk6UUN3ME2wMlA5PDl5IN88US=>	M{LJVXNCVkeHUh?=
KURAMOCHI	M2f0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;4V3ZKSzVyPUCuNFg2ODlizszN	NGHrVnlUSU6JRWK=
A427	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HncWlEPTB;MD6wPFUyOiEQvF2=	NIHHSVZUSU6JRWK=
A3-KAW	NXTYOlROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonjTWM2OD1yLkC4OVY3KM7:TR?=	MWrTRW5ITVJ?
LS-123	M4f5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7uRXVuUUN3ME2wMlA5PzF7IN88US=>	MlWzV2FPT0WU
LoVo	MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMEi3NkDPxE1?	NY\OWJB5W0GQR1XS
PA-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLEdpZKSzVyPUCuNFg4PjlizszN	MULTRW5ITVJ?
CP50-MEL-B	NXry[pZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWW2b\|JiUUN3ME2wMlA5Pzl\|IN88US=>	M2r0WXNCVkeHUh?=
A431	NGnVe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE[4SVBKSzVyPUCuNFg5ODFizszN	Mn2zV2FPT0WU
HCT-116	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXvOHh3UUN3ME2wMlA5QDB{IN88US=>	M1jscHNCVkeHUh?=
A4-Fuk	NULjWINCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XGbWlEPTB;MD6wPFk1PyEQvF2=	MWHTRW5ITVJ?
RPMI-6666	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrjN3JsUUN3ME2wMlA5QTZ5IN88US=>	NYDkOJpEW0GQR1XS
Calu-6	M4D2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LhS2lEPTB;MD6wPVAzQSEQvF2=	MmrKV2FPT0WU
KMOE-2	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXk[\|lKSzVyPUCuNFkxOzlizszN	NV3peIF2W0GQR1XS
A704	NGXaXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnQb2ZKSzVyPUCuNFkyPSEQvF2=	NULHc4xkW0GQR1XS
HO-1-N-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwMEmyOFkh\|ryP	MXvTRW5ITVJ?
NCI-H2122	MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLONVVKSzVyPUCuNFk{PzhizszN	MoXmV2FPT0WU
U-698-M	M4jVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYG0UId7UUN3ME2wMlA6PDB7IN88US=>	M3r1NXNCVkeHUh?=
IST-SL2	NHra[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mke1TWM2OD1yLkC5OFY5KM7:TR?=	MlO0V2FPT0WU
TE-10	NFjBem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMEm1PFQh\|ryP	MUjTRW5ITVJ?
PANC-03-27	NELLbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfOdYxrUUN3ME2wMlA6PjdzIN88US=>	MkXMV2FPT0WU
KYSE-410	MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfIcJFKSzVyPUCuNFk4QTdizszN	NF\1TGhUSU6JRWK=
TE-8	NY\NWI81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXW1fXI{UUN3ME2wMlA6QDh3IN88US=>	NH7JZotUSU6JRWK=
MN-60	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXBTWM2OD1yLkC5PFk4KM7:TR?=	M1G4N3NCVkeHUh?=
NCI-H460	NE\FU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fuOWlEPTB;MD6xNFA6KM7:TR?=	NV7XeoNbW0GQR1XS
LB771-HNC	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rtWWlEPTB;MD6xNFI2PSEQvF2=	MYPTRW5ITVJ?
ES4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwMUCyOlQh\|ryP	NV;veXhlW0GQR1XS
HUTU-80	NV;yW2FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTy[FVqUUN3ME2wMlExOzZ3IN88US=>	MUfTRW5ITVJ?
647-V	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj5S5hDUUN3ME2wMlExPDB6IN88US=>	NYnZWIx[W0GQR1XS
HTC-C3	NVHObVhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\ZO2lEPTB;MD6xNFQ{OiEQvF2=	M1XocXNCVkeHUh?=
NTERA-S-cl-D1	M{jDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMUC0OFgh\|ryP	NUjOU5hSW0GQR1XS
A2058	NGP6OGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjwTWM2OD1yLkGwOlU2KM7:TR?=	MlvFV2FPT0WU
MZ1-PC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMUC4N{DPxE1?	MYHTRW5ITVJ?
J82	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Hid2lEPTB;MD6xNFg5PCEQvF2=	M320TXNCVkeHUh?=
ARH-77	MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLidXFKSzVyPUCuNVEh\|ryP	MoXWV2FPT0WU
Ca9-22	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYH6[Jo6UUN3ME2wMlEyOTJ6IN88US=>	NGTRfXpUSU6JRWK=
NCI-H1648	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfz[G9KSzVyPUCuNVEzQDZizszN	NUj4cpIzW0GQR1XS
MC116	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\kTWM2OD1yLkGxN\|M4KM7:TR?=	NXHzWWdTW0GQR1XS
EoL-1-cell	M1TUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjNPGRGUUN3ME2wMlEyPDZ5IN88US=>	MkX1V2FPT0WU
PANC-10-05	M1r1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYC2XVBKUUN3ME2wMlEyPDlzIN88US=>	NGW4UXFUSU6JRWK=
SF539	M3PhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\mc2lEPTB;MD6xNVYyPiEQvF2=	NH;pZ5lUSU6JRWK=
ES8	NE\JZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEf1O45KSzVyPUCuNVE3OzNizszN	NYDVT2FbW0GQR1XS
NCI-H810	NVnrOYhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzLUpl7UUN3ME2wMlEyPjZ2IN88US=>	MnrEV2FPT0WU
J-RT3-T3-5	M1HUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofQTWM2OD1yLkGxO\|Uh\|ryP	MmfVV2FPT0WU
NY	M160OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HXR2lEPTB;MD6xNVgyPyEQvF2=	Mn;sV2FPT0WU
NCI-SNU-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjBV4lLUUN3ME2wMlEzOTR6IN88US=>	MoHPV2FPT0WU
EFM-19	M136OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLjZnlKSzVyPUCuNVI{PzRizszN	MmKxV2FPT0WU
HCC1806	M4rzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXWTWM2OD1yLkGyN\|g{KM7:TR?=	MVzTRW5ITVJ?
HCE-T	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfCTWM2OD1yLkGyOVMyKM7:TR?=	MVrTRW5ITVJ?
HT-1376	NUDKd3c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkewTWM2OD1yLkGyOlY5KM7:TR?=	MYLTRW5ITVJ?
BE-13	M4Dmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3BTWM2OD1yLkGyPFY3KM7:TR?=	NH\hbHRUSU6JRWK=
NCI-H520	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;kTWM2OD1yLkGyPFY4KM7:TR?=	NV3qd5U2W0GQR1XS
SK-MES-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\PUmxTUUN3ME2wMlEzQTF\|IN88US=>	NEHpToVUSU6JRWK=
SNU-423	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVy0clNJUUN3ME2wMlEzQTF2IN88US=>	MnfHV2FPT0WU
Ramos-2G6-4C10	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\0PJczUUN3ME2wMlEzQTF4IN88US=>	MYHTRW5ITVJ?
EW-18	NYH0XItET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHM[oFLUUN3ME2wMlE{ODJ4IN88US=>	MWXTRW5ITVJ?
NCI-H2087	NVvGPHlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMUOwNlch\|ryP	NFryfINUSU6JRWK=
COLO-792	NFu4OnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfzTWM2OD1yLkGzNVY2KM7:TR?=	NVf2T5pJW0GQR1XS
QIMR-WIL	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLtZ5BKSzVyPUCuNVMzOjNizszN	MXXTRW5ITVJ?
ACHN	NELtTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3GyfGlEPTB;MD6xN\|I1PyEQvF2=	NF[0bIhUSU6JRWK=
RPMI-8866	NYDkUph{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMUOyOlEh\|ryP	MoTuV2FPT0WU
SK-LU-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLiTWM2OD1yLkGzOFQ6KM7:TR?=	Mn3yV2FPT0WU
SK-UT-1	M3fmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMUO2Nlgh\|ryP	M3LnZXNCVkeHUh?=
MFE-296	MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLhTWM2OD1yLkGzPFY1KM7:TR?=	MWjTRW5ITVJ?
RD	NUPTO\|JTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13LPWlEPTB;MD6xN\|k6PyEQvF2=	NWXaNG0{W0GQR1XS
LS-411N	M1XlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfhfYFKSzVyPUCuNVQzQTVizszN	MWnTRW5ITVJ?
NCI-H747	NIH3T4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XodmlEPTB;MD6xOFMh\|ryP	M3POb3NCVkeHUh?=
ES6	M{\UUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTzTWM2OD1yLkG0N\|Yh\|ryP	M{nsTnNCVkeHUh?=
TE-1	Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMUS0NFch\|ryP	M2DNUHNCVkeHUh?=
SJSA-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHkR2RKSzVyPUCuNVQ4ODdizszN	MXLTRW5ITVJ?
NCI-H1355	MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMUWyPVMh\|ryP	M4PpXnNCVkeHUh?=
HEL	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1yyUWlEPTB;MD6xOVQ1PyEQvF2=	NYLpWIRYW0GQR1XS
639-V	NFrWc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwMUW1PVYh\|ryP	MnHOV2FPT0WU
AN3-CA	M{HWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DLb2lEPTB;MD6xOVY{QSEQvF2=	Mo[4V2FPT0WU
SK-MEL-2	NH3pZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTvflJKSzVyPUCuNVU3PjhizszN	MUHTRW5ITVJ?
SW872	NHLabItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHT0NFJKSzVyPUCuNVYxPDJizszN	M{nr[HNCVkeHUh?=
DU-4475	M2Ltdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMU[xOlIh\|ryP	M1ywUXNCVkeHUh?=
YKG-1	NVLGcGhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DIb2lEPTB;MD6xOlI4OyEQvF2=	NHf2SmdUSU6JRWK=
GT3TKB	MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMU[yPFMh\|ryP	MXTTRW5ITVJ?
GB-1	NUjacXdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4[5[GlEPTB;MD6xOlQzPCEQvF2=	M33H[nNCVkeHUh?=
KARPAS-422	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTSbJZIUUN3ME2wMlE3PTd2IN88US=>	MoLSV2FPT0WU
ATN-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17PU2lEPTB;MD6xOlY2PiEQvF2=	NWDCW4poW0GQR1XS
HLE	MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnraTWM2OD1yLkG2PFc4KM7:TR?=	MoD5V2FPT0WU
D-542MG	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvBTWM2OD1yLkG2PVg3KM7:TR?=	MVrTRW5ITVJ?
EB-3	NVz6dFg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXCfGtKUUN3ME2wMlE4OzFizszN	Moq2V2FPT0WU
HCC1143	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LwcmlEPTB;MD6xO\|M6PiEQvF2=	MXTTRW5ITVJ?
DJM-1	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PjZ2lEPTB;MD6xO\|Q2OSEQvF2=	NVrWXoJIW0GQR1XS
BT-474	Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvTeGNKSzVyPUCuNVc1QDlizszN	MU\TRW5ITVJ?
BB65-RCC	MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnzTWM2OD1yLkG3OVQ2KM7:TR?=	MXvTRW5ITVJ?
NCI-H292	MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMUe2NFEh\|ryP	NHnJS2ZUSU6JRWK=
MKN28	M3zCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\NcYlKSzVyPUCuNVc3PTNizszN	NHHLTYlUSU6JRWK=
TK10	M2\wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnLTWM2OD1yLkG3O\|AzKM7:TR?=	NV7SUnFwW0GQR1XS
TYK-nu	NUGzPJFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{P4PGlEPTB;MD6xO\|k1QSEQvF2=	NGDiOotUSU6JRWK=
8305C	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml:2TWM2OD1yLkG3PVcyKM7:TR?=	M4Ds[HNCVkeHUh?=
MV-4-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjsTWM2OD1yLkG3PVc4KM7:TR?=	MoTvV2FPT0WU
NCI-H522	M4K4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMUiwPVQh\|ryP	MmP0V2FPT0WU
Hs-578-T	NYHTO41IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\pTWM2OD1yLkG4NlkzKM7:TR?=	NV:5PYxZW0GQR1XS
LCLC-103H	M1z1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPOTWM2OD1yLkG4OVI4KM7:TR?=	NWXxPZh3W0GQR1XS
MHH-ES-1	M1P4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33oVmlEPTB;MD6xPFYzQSEQvF2=	Mk\CV2FPT0WU
NCI-H441	M{DnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrQZWRKSzVyPUCuNVkyPDhizszN	NXLRWXhxW0GQR1XS
AM-38	M{PqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PNVmlEPTB;MD6xPVIzPSEQvF2=	MXzTRW5ITVJ?
SW1783	M1jUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMUmzNFUh\|ryP	NGnVeXpUSU6JRWK=
SK-HEP-1	M{LvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMUm2N\|ch\|ryP	NGjDWItUSU6JRWK=
OAW-28	NIjNeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrD[I1yUUN3ME2wMlIxOTd6IN88US=>	MV3TRW5ITVJ?
TE-15	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7DZXlKUUN3ME2wMlIxOjV{IN88US=>	NFO4VYtUSU6JRWK=
HCE-4	NHjXdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTMbJBKSzVyPUCuNlAzQDRizszN	M1iwNXNCVkeHUh?=
JiyoyeP-2003	NWDCXYxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTSSGhKSzVyPUCuNlA{OzZizszN	MorwV2FPT0WU
OVCAR-4	NFzUfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;HeJBKSzVyPUCuNlA3OjhizszN	MmfxV2FPT0WU
SNU-449	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzVTlZKSzVyPUCuNlA4QTdizszN	MV\TRW5ITVJ?
SBC-5	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1z0SGlEPTB;MD6yNVIyPSEQvF2=	Mk\3V2FPT0WU
T84	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4j1VmlEPTB;MD6yNVI1QCEQvF2=	MWfTRW5ITVJ?
LP-1	NXPpVmdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTNeHJIUUN3ME2wMlIyOzB{IN88US=>	MXTTRW5ITVJ?
MG-63	NXH1RXhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jDWGlEPTB;MD6yNVM5OiEQvF2=	MnzLV2FPT0WU
OAW-42	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMkG0O\|gh\|ryP	MWrTRW5ITVJ?
L-540	NG\hc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TjZ2lEPTB;MD6yNVU6QCEQvF2=	MoC2V2FPT0WU
RH-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHyTWM2OD1yLkKyNlQzKM7:TR?=	MXnTRW5ITVJ?
HCT-15	Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELUXFBKSzVyPUCuNlI1QDRizszN	MV\TRW5ITVJ?
OCUB-M	MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwMkK0PFgh\|ryP	M4TKU3NCVkeHUh?=
GP5d	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3ETWM2OD1yLkKyOVI5KM7:TR?=	Mn\pV2FPT0WU
NCI-H2030	M4e4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMkK3N\|Qh\|ryP	MmPzV2FPT0WU
ML-2	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HZbWlEPTB;MD6yNlg5QSEQvF2=	NVXUXI83W0GQR1XS
CAL-39	NVnXR3FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXWUYw1UUN3ME2wMlIzQTN4IN88US=>	NHTXXmZUSU6JRWK=
MIA-PaCa-2	NH7zOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH[5bY5KSzVyPUCuNlMzQDdizszN	NVHaTIVVW0GQR1XS
TE-9	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzVOnd2UUN3ME2wMlI{OzJizszN	NXXiRmRJW0GQR1XS
LB2518-MEL	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkC1TWM2OD1yLkKzN\|czKM7:TR?=	NWHNTWhNW0GQR1XS
DB	M1n1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwMkO0N\|gh\|ryP	M1jkb3NCVkeHUh?=
NCI-H596	M1vMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMkO1O\|Eh\|ryP	MYDTRW5ITVJ?
SW1990	NIPRV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r2bWlEPTB;MD6yN\|k1PiEQvF2=	NW\TPGY{W0GQR1XS
P30-OHK	MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrkbnUxUUN3ME2wMlI1ODVizszN	MkHsV2FPT0WU
ALL-PO	M4n3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH4PYdKSzVyPUCuNlQyPjlizszN	NFm4WnFUSU6JRWK=
Saos-2	NVe3VnVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnl[G9FUUN3ME2wMlI1PTdzIN88US=>	M33uPHNCVkeHUh?=
MFH-ino	M3;RZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLNR5pKSzVyPUCuNlQ3QTJizszN	NIXWTWJUSU6JRWK=
OE33	MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMkWxNUDPxE1?	MlXVV2FPT0WU
Calu-3	NGK3VJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;WTWM2OD1yLkK1Nlk4KM7:TR?=	NHeyUIxUSU6JRWK=
HT	NYja[VBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMkW2NlEh\|ryP	NHHiUFhUSU6JRWK=
LXF-289	M3H4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\2d4RKSzVyPUCuNlU6QDRizszN	M2XwbXNCVkeHUh?=
KGN	NWTGZm9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXPVoFDUUN3ME2wMlI3ODh7IN88US=>	NIX3eGlUSU6JRWK=
NCI-H1417	M4OzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHUb4J2UUN3ME2wMlI3PTJ2IN88US=>	MYXTRW5ITVJ?
SF126	MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwMkezNFIh\|ryP	NHfLZ3hUSU6JRWK=
SAS	NWrrfIhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfTTWM2OD1yLkK3N\|A5KM7:TR?=	NIL6R\|hUSU6JRWK=
22RV1	M1PIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7Pe\|VkUUN3ME2wMlI4Ozd6IN88US=>	NWLJSWVXW0GQR1XS
GI-1	NUj2PYhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjudFZKSzVyPUCuNlc1QDdizszN	NULCU2ZuW0GQR1XS
ES3	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mle1TWM2OD1yLkK3O\|Y{KM7:TR?=	NHPySohUSU6JRWK=
NB1	NFjJR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMke4O\|Yh\|ryP	M13vSnNCVkeHUh?=
NCI-H650	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLleFltUUN3ME2wMlI5OzB{IN88US=>	M1f1UXNCVkeHUh?=
IST-MES1	MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHCWXVKSzVyPUCuNlg2PTRizszN	M3TEVHNCVkeHUh?=
UM-UC-3	NEH4W45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvp[WJKSzVyPUCuNlkyPCEQvF2=	NI\TWpFUSU6JRWK=
CAL-120	NIm0boVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHiTWM2OD1yLkK5OlMyKM7:TR?=	MoLOV2FPT0WU
UACC-62	M{X3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjPXnVKSzVyPUCuN\|AzPDFizszN	M4W5PHNCVkeHUh?=
TE-11	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\ETWM2OD1yLkOwNlQ6KM7:TR?=	M{fVNHNCVkeHUh?=
MKN1	MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwM{CzOkDPxE1?	NEn0Um1USU6JRWK=
KS-1	NU\BZmNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVGzeIM4UUN3ME2wMlMxPTJ4IN88US=>	M{\1fHNCVkeHUh?=
GCIY	NY\LO29vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwM{GwNFIh\|ryP	NEOxOmhUSU6JRWK=
OVCAR-5	M2jocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ewZ2lEPTB;MD6zNVExPiEQvF2=	Mn76V2FPT0WU
U-266	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PVRmlEPTB;MD6zNVE1PyEQvF2=	M4TQWnNCVkeHUh?=
Calu-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlH2TWM2OD1yLkOxNlg6KM7:TR?=	M3XmeHNCVkeHUh?=
SK-LMS-1	MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M330UmlEPTB;MD6zNVQzQSEQvF2=	MnPlV2FPT0WU
COLO-741	NIT0TpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwM{G2NVQh\|ryP	MknjV2FPT0WU
RPMI-8226	M{Lx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\mTWM2OD1yLkOxOlQyKM7:TR?=	M3TDO3NCVkeHUh?=
KM12	MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwM{G4N{DPxE1?	MX\TRW5ITVJ?
NMC-G1	MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkG3TWM2OD1yLkOxPFYh\|ryP	MnjvV2FPT0WU
SJRH30	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfNfYVKSzVyPUCuN\|IxPTJizszN	Mnf3V2FPT0WU
COR-L105	Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XJT2lEPTB;MD6zNlIyQCEQvF2=	NH7JZ5FUSU6JRWK=
IM-9	NETrZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXFOZdKSzVyPUCuN\|MxOjFizszN	NYLoZlZnW0GQR1XS
TE-12	NXvtSopzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwM{OzNVch\|ryP	MULTRW5ITVJ?
KG-1	M2P2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwM{O0N\|Ih\|ryP	MlzEV2FPT0WU
U251	NUHWepp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{S4dGlEPTB;MD6zN\|Q2PiEQvF2=	MlHCV2FPT0WU
EFO-27	NYjXTZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXP4U5FiUUN3ME2wMlM{QTVzIN88US=>	NX7KZYY6W0GQR1XS
EW-24	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHu5[ZBKSzVyPUCuN\|M6QDRizszN	NWLxbI91W0GQR1XS
SF295	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmqwTWM2OD1yLkOzPVk6KM7:TR?=	MkTBV2FPT0WU
MC-IXC	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwM{S1JO69VQ>?	Ml73V2FPT0WU
NCI-H2405	NX7TfIs5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\KTWM2OD1yLkO0O\|MzKM7:TR?=	MlXxV2FPT0WU
NCI-H2009	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwM{S3N\|kh\|ryP	MonFV2FPT0WU
LB1047-RCC	NUP0SWV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXSTWM2OD1yLkO1PFE2KM7:TR?=	MVfTRW5ITVJ?
KNS-81-FD	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwM{[2Olch\|ryP	M{fCZ3NCVkeHUh?=
HOP-92	M2TLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfhTWM2OD1yLkO2PFMh\|ryP	NGXJS3hUSU6JRWK=
L-428	NYXtW3BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEOxRVJKSzVyPUCuN\|cxOTZizszN	MXfTRW5ITVJ?
C3A	M1jRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm[3TWM2OD1yLkO3N\|c6KM7:TR?=	NEWwV2lUSU6JRWK=
NCI-H1792	MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwM{e2OVUh\|ryP	MlLmV2FPT0WU
HuH-7	M1OyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwM{e5NUDPxE1?	MXTTRW5ITVJ?
AGS	NGr1WohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwM{i2N\|gh\|ryP	MlvOV2FPT0WU
HT-1197	NH6zVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwM{m0OkDPxE1?	NX;1RYxZW0GQR1XS
CGTH-W-1	NFHZRnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPtTWM2OD1yLkO5PVE{KM7:TR?=	MUHTRW5ITVJ?
KNS-42	M4XHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUizVmtuUUN3ME2wMlQxODR3IN88US=>	M1K4enNCVkeHUh?=
HuO-3N1	NVixOoR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HDU2lEPTB;MD60NFA2PSEQvF2=	Ml\qV2FPT0WU
VMRC-RCZ	M3f2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33NN2lEPTB;MD60NFMxOyEQvF2=	NGnSfplUSU6JRWK=
SW954	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwNECzN\|Uh\|ryP	NHHUNHFUSU6JRWK=
MES-SA	NF3lb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPMcnRXUUN3ME2wMlQxPTB3IN88US=>	M2TkRXNCVkeHUh?=
Ca-Ski	M4nwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEG5fYlKSzVyPUCuOFA2OjRizszN	MlvjV2FPT0WU
SW13	NE\OdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYe0do86UUN3ME2wMlQxPjJ4IN88US=>	NG\xPHBUSU6JRWK=
NCI-H1437	NFXhZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TzPWlEPTB;MD60NFgxPSEQvF2=	MYPTRW5ITVJ?
U-118-MG	NVXBU\|c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwNEC5NFQh\|ryP	NWniXpdqW0GQR1XS
NCI-H1734	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\HfmlEPTB;MD60NlAyOyEQvF2=	MXrTRW5ITVJ?
HDLM-2	M{fnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXSOllnUUN3ME2wMlQzODN\|IN88US=>	MV7TRW5ITVJ?
AU565	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mme0TWM2OD1yLkSyOFY5KM7:TR?=	MlrkV2FPT0WU
FADU	NEDkd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwNEK2OFkh\|ryP	MVTTRW5ITVJ?
OS-RC-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mme1TWM2OD1yLkSzNFg{KM7:TR?=	NX;PUlRLW0GQR1XS
CAMA-1	NIXvOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\ITWM2OD1yLkSzOlI3KM7:TR?=	MXzTRW5ITVJ?
MONO-MAC-6	NVS5eIRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwNEO4OFkh\|ryP	MoHxV2FPT0WU
LB831-BLC	M4m4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTITWM2OD1yLkS0N\|cyKM7:TR?=	MVfTRW5ITVJ?
SW982	NF25UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXyTWM2OD1yLkS0OVI5KM7:TR?=	MluyV2FPT0WU
SCC-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DRXmlEPTB;MD60OFU4QSEQvF2=	MXnTRW5ITVJ?
C32	NV:2dGExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvVZ\|JKSzVyPUCuOFUzOjlizszN	MXjTRW5ITVJ?
BFTC-909	M1vieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\BVWlEPTB;MD60OVI6QSEQvF2=	MlvJV2FPT0WU
MEG-01	M2\FWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwNEWzO\|Mh\|ryP	NH;LU2xUSU6JRWK=
M14	NXq2PFBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXIcopGUUN3ME2wMlQ2QTd7IN88US=>	NEj4[YVUSU6JRWK=
MPP-89	NI\N[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PGUWlEPTB;MD60OlI2PiEQvF2=	NVfhbIZWW0GQR1XS
HCC1937	NYHPW2RoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\QNWlEPTB;MD60OlM5PCEQvF2=	NXPq[Ik5W0GQR1XS
SW837	NVKyVJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHpfVl5UUN3ME2wMlQ3PzJ{IN88US=>	Mof1V2FPT0WU
DU-145	M36xNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzXcWJKSzVyPUCuOFY4OjlizszN	NHLsVVJUSU6JRWK=
LB996-RCC	NXTuU2lJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLPRlN[UUN3ME2wMlQ4ODV2IN88US=>	NHfIb\|RUSU6JRWK=
C8166	NYrYfpNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLEVnJKSzVyPUCuOFc1KM7:TR?=	M4SxfXNCVkeHUh?=
MOLT-4	NVzBXIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwNEe3N\|Qh\|ryP	NHPHOm5USU6JRWK=
DMS-53	NXLmSIJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWroNII1UUN3ME2wMlQ4QDB7IN88US=>	NITRXG9USU6JRWK=
TE-5	NUfyXGE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\BVmlEPTB;MD60PFMxPSEQvF2=	M{i1XXNCVkeHUh?=
KYSE-520	M1ezbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjSd5hKSzVyPUCuOFg{PDNizszN	MoTzV2FPT0WU
Detroit562	NGjDOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfudGwyUUN3ME2wMlQ5QDZizszN	NFHIco1USU6JRWK=
SIMA	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fM[WlEPTB;MD60PVQyPyEQvF2=	MVfTRW5ITVJ?
NCI-H1651	M131bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTSdFhrUUN3ME2wMlQ6PjdizszN	NUHMNY9IW0GQR1XS
HCC1599	NECyS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDEbWQ4UUN3ME2wMlQ6QTV3IN88US=>	Mnm3V2FPT0WU
ABC-1	M4[0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwNUC0PVYh\|ryP	NVnySYtuW0GQR1XS
CAL-33	NHvLRZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnNcGVKSzVyPUCuOVA5PDRizszN	NGfUdFdUSU6JRWK=
OPM-2	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\vTWM2OD1yLkWwPVM4KM7:TR?=	Ml\5V2FPT0WU
RPMI-7951	M{DnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17jS2lEPTB;MD61NFk2PyEQvF2=	NWPUcGs3W0GQR1XS
HT-1080	M3vHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2m4NmlEPTB;MD61NVEyQSEQvF2=	M37Td3NCVkeHUh?=
LC4-1	NXrOU3BNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HZbGlEPTB;MD61NVQxOyEQvF2=	NUGyR3hHW0GQR1XS
OVCAR-3	Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vTTWlEPTB;MD61NVU4KM7:TR?=	M2DvWHNCVkeHUh?=
CAPAN-1	NXK5VodwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwNUKyPFgh\|ryP	NHXESnVUSU6JRWK=
SK-OV-3	NH7hTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33RT2lEPTB;MD61NlQ{PCEQvF2=	M4XLXnNCVkeHUh?=
HuP-T3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XleWlEPTB;MD61NlgzPyEQvF2=	NYLqXHllW0GQR1XS
NCI-H838	M3\uU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vacWlEPTB;MD61Nlg1QSEQvF2=	NHjPPIFUSU6JRWK=
K5	MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLDTWM2OD1yLkWzNlAyKM7:TR?=	M4DJb3NCVkeHUh?=
CAL-72	M3nibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwNUOzPFch\|ryP	MnfnV2FPT0WU
NH-12	NICxfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFP0NVhKSzVyPUCuOVM6PTlizszN	NXfCcm5lW0GQR1XS
SNB75	NEGzb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwNUW3N{DPxE1?	NUP0fnQxW0GQR1XS
BPH-1	NVjufpRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7JUJJKSzVyPUCuOVY{PDRizszN	Mmm0V2FPT0WU
NOMO-1	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwNU[zO\|Ih\|ryP	MlLqV2FPT0WU
G-402	MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnyTWM2OD1yLkW2OFk6KM7:TR?=	NEfINYFUSU6JRWK=
NCI-H2052	M1u0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jmXWlEPTB;MD61Olc1OSEQvF2=	NVvvPI9nW0GQR1XS
RCM-1	M4TaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLETWM2OD1yLkW3NVY3KM7:TR?=	MVPTRW5ITVJ?
COR-L279	NVzLNndKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoSzTWM2OD1yLkW3NVg2KM7:TR?=	MYXTRW5ITVJ?
A253	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHiOndKSzVyPUCuOVc2OjVizszN	NX;WOXFHW0GQR1XS
SK-MM-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGqyOY1KSzVyPUCuOVc3PzlizszN	M33LcXNCVkeHUh?=
NCI-H1703	NILZR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3KxeWlEPTB;MD61PVQzPyEQvF2=	M3HaUXNCVkeHUh?=
UACC-257	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFftWXlKSzVyPUCuOVk1QDdizszN	MVrTRW5ITVJ?
KALS-1	NUP5bpNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWH3[2VsUUN3ME2wMlYxODFzIN88US=>	NH:wWopUSU6JRWK=
ES5	M{XjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[2RnhKSzVyPUCuOlA1QCEQvF2=	MmnxV2FPT0WU
MHH-CALL-2	NYOzUo9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTkTWM2OD1yLk[wPFg5KM7:TR?=	NUjOcZZLW0GQR1XS
ChaGo-K-1	NF;JbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHCTWM2OD1yLk[xNlI6KM7:TR?=	M1XWZnNCVkeHUh?=
TGBC1TKB	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrSPWFKSzVyPUCuOlE6QCEQvF2=	NXPZSWJzW0GQR1XS
KU-19-19	M3Prfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwNkS1PFYh\|ryP	MnrJV2FPT0WU
COLO-684	MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHHcWM1UUN3ME2wMlY2PjFzIN88US=>	MYfTRW5ITVJ?
LS-1034	NWWwcIdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPLe5VKSzVyPUCuOlU5OTlizszN	NILRbFVUSU6JRWK=
RT-112	NFzDUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrEc2NxUUN3ME2wMlY3PTh5IN88US=>	NWjHVYJYW0GQR1XS
Capan-2	NUXIelhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYr4d4ZlUUN3ME2wMlY3PjJ{IN88US=>	MnrlV2FPT0WU
HSC-4	M2faNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXTd49KSzVyPUCuOlY3QThizszN	MkPFV2FPT0WU
COLO-824	Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTyTWM2OD1yLk[3PFI{KM7:TR?=	M3\TOXNCVkeHUh?=
NCI-H2170	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vvW2lEPTB;MD62PFI2QCEQvF2=	MYDTRW5ITVJ?
GDM-1	M1:wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDkfIlKSzVyPUCuOlg1QTRizszN	NUHPfVhNW0GQR1XS
KP-4	M1fTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfMXGVKSzVyPUCuOlk2PzNizszN	MXTTRW5ITVJ?
VA-ES-BJ	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwNkm5PFYh\|ryP	NH7EZ2NUSU6JRWK=
KM-H2	NUXsZ5Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\rdmlEPTB;MD63NFA6OSEQvF2=	MWjTRW5ITVJ?
HH	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7qW5NZUUN3ME2wMlcxPjZ{IN88US=>	NV\GcFNIW0GQR1XS
DK-MG	NYLjeWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTBwN{GwNVYh\|ryP	MoXwV2FPT0WU
VM-CUB-1	NWXnSGxST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwN{GyOVkh\|ryP	NFjmOYRUSU6JRWK=
COLO-829	M1H2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzZTWM2OD1yLkexPVg2KM7:TR?=	NWT3RmJiW0GQR1XS
OMC-1	M{\i[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwN{KxNFQh\|ryP	MUfTRW5ITVJ?
NB12	NHvK[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwN{K1NFQh\|ryP	NW\TOmxiW0GQR1XS
NCI-H28	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrQTWM2OD1yLke0NFg{KM7:TR?=	Mn\MV2FPT0WU
A673	M{X3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwN{WxO\|ch\|ryP	NIr3PHlUSU6JRWK=
LB2241-RCC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwN{[wPFch\|ryP	NXG5ZZBPW0GQR1XS
CCRF-CEM	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwN{ewOVIh\|ryP	M{nhTXNCVkeHUh?=
NCI-H510A	M3zqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwN{exPFYh\|ryP	M1\0Z3NCVkeHUh?=
SW48	NF;EWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnl[JRlUUN3ME2wMlc4OzN\|IN88US=>	NIjJ[mhUSU6JRWK=
NCI-H2081	NVGwS4JxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jLUmlEPTB;MD63PFE1PyEQvF2=	MXfTRW5ITVJ?
RMG-I	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwN{iyNVIh\|ryP	MmTyV2FPT0WU
LU-99A	MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDRdohKSzVyPUCuO\|g1OTNizszN	M1j5[HNCVkeHUh?=
KP-N-YS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwN{i5NlEh\|ryP	M4XN[3NCVkeHUh?=
MDA-MB-231	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTyToxKSzVyPUCuPFAyOzFizszN	MWHTRW5ITVJ?
U031	NYfBfJA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV:xW2E2UUN3ME2wMlgyPDJ\|IN88US=>	MXXTRW5ITVJ?
EVSA-T	M1n2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkO2TWM2OD1yLkixOlczKM7:TR?=	M37nTnNCVkeHUh?=
MDA-MB-157	NEmwXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vZSGlEPTB;MD64NlI4OSEQvF2=	NGDCeVJUSU6JRWK=
EHEB	MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnGTWM2OD1yLkiyNlc3KM7:TR?=	NF;SS2dUSU6JRWK=
KINGS-1	NYPKZ4toT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zPbmlEPTB;MD64NlU2PSEQvF2=	MknzV2FPT0WU
23132-87	NGjR[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TuWWlEPTB;MD64Nlg1OyEQvF2=	MWPTRW5ITVJ?
EFO-21	NHLnW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwOESwPFkh\|ryP	NFjpOWVUSU6JRWK=
DOK	NYTYUYRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVm4S\|FFUUN3ME2wMlg1QCEQvF2=	Mm[2V2FPT0WU
NCI-H2171	MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TEdGlEPTB;MD64OFk3KM7:TR?=	NEXneGdUSU6JRWK=
NCI-SNU-5	NFXsRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rYeWlEPTB;MD64OVU4KM7:TR?=	MmLUV2FPT0WU
SK-N-DZ	MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLJfoxxUUN3ME2wMlg2QTR\|IN88US=>	NWjuPY4zW0GQR1XS
SNU-C2B	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTjTWM2OD1yLki2PFAyKM7:TR?=	NIHiUIZUSU6JRWK=
CP66-MEL	NX[3SWl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwOEexNUDPxE1?	MoP6V2FPT0WU
SN12C	Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwOEi2N\|ch\|ryP	Mk\kV2FPT0WU
A172	MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWK3[mxJUUN3ME2wMlg5Pjl6IN88US=>	Mlz3V2FPT0WU
NCI-H2347	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX72TW82UUN3ME2wMlg5PzV\|IN88US=>	NVr4UYR2W0GQR1XS
NCI-H2228	NVrqUYdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnpeGJKSzVyPUCuPFk{OzlizszN	M2rkXnNCVkeHUh?=
SNU-387	NHvScFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfMbmZ2UUN3ME2wMlkxOjZ2IN88US=>	MUTTRW5ITVJ?
SK-MEL-24	MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlS4TWM2OD1yLkmxN\|Q1KM7:TR?=	MmP2V2FPT0WU
MDA-MB-468	M2LVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HPRWlEPTB;MD65NVc{KM7:TR?=	NInLV5pUSU6JRWK=
NCI-H1694	NFjyRnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3ITWM2OD1yLkmxPFc3KM7:TR?=	NFXSWJhUSU6JRWK=
CCF-STTG1	NXLUXZdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwOUK2N\|ch\|ryP	M{fRRnNCVkeHUh?=
K052	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjkOGtKSzVyPUCuPVQxPDdizszN	MXHTRW5ITVJ?
NCI-H446	MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLrbVczUUN3ME2wMlk2ODFizszN	M{\0WHNCVkeHUh?=
MFE-280	NV3wdFBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHT[FFKSzVyPUCuPVYzQTFizszN	NUSzWHE4W0GQR1XS
KU812	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvaNpRMUUN3ME2wMlk6Ozh7IN88US=>	NXG3S4RMW0GQR1XS
MDA-MB-361	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvTV2plUUN3ME2wMlk6Pzd5IN88US=>	M1nWTXNCVkeHUh?=
Raji	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NImyeYJKSzVyPUGuNFIzPjdizszN	M2r6NHNCVkeHUh?=
TE-6	NIrZbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTFwMEO1OlYh\|ryP	MXPTRW5ITVJ?
CAL-148	MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWT0fnY6UUN3ME2xMlA1PDR\|IN88US=>	Ml;OV2FPT0WU
NCI-H1963	M3;Y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHsOI1KSzVyPUGuNFQ2PTNizszN	Ml3mV2FPT0WU
SK-N-AS	NH25W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTFwMES2PFUh\|ryP	MU\TRW5ITVJ?
RERF-LC-MS	NHP4c\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXiTWM2OD1zLkC2N\|Q6KM7:TR?=	MXnTRW5ITVJ?
BEN	NEfGdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrDVGVKSzVyPUGuNFcyOzdizszN	NYTxZVUyW0GQR1XS
CAS-1	NUe5WIdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXneml{UUN3ME2xMlA6OTJ\|IN88US=>	M2KyZnNCVkeHUh?=
SW780	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETLXpdKSzVyPUGuNFkyQDFizszN	MmTrV2FPT0WU
LU-65	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTFwMEm0NUDPxE1?	M3L0cXNCVkeHUh?=
D-283MED	NIW1enZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\6[HpKSzVyPUGuNVIzPzJizszN	Mn7QV2FPT0WU
HCC2157	NILz[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nPUGlEPTB;MT6xN\|Y1OiEQvF2=	MV;TRW5ITVJ?
RCC10RGB	MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTDTWM2OD1zLkG0NFA3KM7:TR?=	NID4ZYxUSU6JRWK=
PLC-PRF-5	NVfDUpZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fkdGlEPTB;MT6xOVIzQSEQvF2=	NVjObZBnW0GQR1XS
H4	NFfMbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjZUppKSzVyPUGuNVU1OzlizszN	MX3TRW5ITVJ?
TUR	NVe2XVdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTFwMUW3OVIh\|ryP	NELjSlFUSU6JRWK=
NCI-H2141	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTFwMUi5OFYh\|ryP	M3;RO3NCVkeHUh?=
PFSK-1	NF3XcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW[xcJU{UUN3ME2xMlIxPTN{IN88US=>	NHG1Z\|VUSU6JRWK=
SK-MEL-28	M4fac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrLTWM2OD1zLkKzNlIyKM7:TR?=	NXnveZRFW0GQR1XS
SCC-9	NUOwdG5rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTFwMkO2OlUh\|ryP	MXPTRW5ITVJ?
T47D	NWnOeWhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUL5dIkxUUN3ME2xMlI{Pjl4IN88US=>	MUTTRW5ITVJ?
TCCSUP	M3rKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfhU4RKSzVyPUGuNlUxOjlizszN	M4LTZ3NCVkeHUh?=
SU-DHL-1	NE\OOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXmTWM2OD1zLkK1NVE5KM7:TR?=	NHu0OIVUSU6JRWK=
HL-60	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofnTWM2OD1zLkK1OVg5KM7:TR?=	MWLTRW5ITVJ?
NCI-H1436	M2rLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTFwMk[xOFkh\|ryP	NGXCbHJUSU6JRWK=
DMS-114	NXHKWY5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn33TWM2OD1zLkK2OlMzKM7:TR?=	NIjMNYRUSU6JRWK=
BOKU	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TZWGlEPTB;MT6yPFA6PSEQvF2=	NF:1PGJUSU6JRWK=
MS-1	MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\4S\|V{UUN3ME2xMlI6ODZ7IN88US=>	MnLvV2FPT0WU
NCI-H661	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTFwM{C0O\|gh\|ryP	NES5U3VUSU6JRWK=
HT-3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvqV5BVUUN3ME2xMlMxPTJ7IN88US=>	MULTRW5ITVJ?
CAL-54	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\1VmlEPTB;MT6zNFczPSEQvF2=	NGjHPI1USU6JRWK=
SW1463	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDETWM2OD1zLkOxPFczKM7:TR?=	M3jWNXNCVkeHUh?=
COLO-668	NECwXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPWSXZKSzVyPUGuN\|MxPTZizszN	MX;TRW5ITVJ?
PANC-08-13	NY\ScXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXWfmNKSzVyPUGuN\|M5ODNizszN	NGq4dYFUSU6JRWK=
BB49-HNC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fve2lEPTB;MT6zOFAyKM7:TR?=	NGHhS5lUSU6JRWK=
M059J	M4r1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfFTHZOUUN3ME2xMlM2QDN{IN88US=>	NGX5bG9USU6JRWK=
NCCIT	NXjJboUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\HTWM2OD1zLkO3PVg5KM7:TR?=	MUfTRW5ITVJ?
LN-405	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHqTWM2OD1zLkO5NlY1KM7:TR?=	MXvTRW5ITVJ?
UMC-11	MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TjSGlEPTB;MT6zPVk6PiEQvF2=	M{nOTHNCVkeHUh?=
NB5	M2nCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLuTWM2OD1zLkSxNlI4KM7:TR?=	MlHlV2FPT0WU
TE-441-T	NIXx[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LXPGlEPTB;MT60NlgyPyEQvF2=	MmKxV2FPT0WU
ME-180	NIDNOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvlUIdKSzVyPUGuOFQ{QTJizszN	MmPPV2FPT0WU
HCC70	NXLSeGp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXPdXNKSzVyPUGuOFYxQTZizszN	MlvpV2FPT0WU
no-10	M{DEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHCTWM2OD1zLkS2NVgyKM7:TR?=	MX\TRW5ITVJ?
JEG-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEC3[GFKSzVyPUGuOVAyOzJizszN	NGXhNllUSU6JRWK=
no-11	Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPPXpJwUUN3ME2xMlUxQDh{IN88US=>	MWXTRW5ITVJ?
CHP-126	NX3KZYJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTFwNU[2PVEh\|ryP	NX;mTms5W0GQR1XS
EGI-1	M1;TSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTFwNUiwNlUh\|ryP	MYTTRW5ITVJ?
D-392MG	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jk[GlEPTB;MT61PVY{KM7:TR?=	M3O2RnNCVkeHUh?=
RT4	M3\UZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXOTWM2OD1zLkW5OlM4KM7:TR?=	NEPVN49USU6JRWK=
A204	NHfrT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7MTWM2OD1zLkW5PFAyKM7:TR?=	MUnTRW5ITVJ?
NCI-H1304	M1\JWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXCW3BKSzVyPUGuOlM2QTFizszN	MmOyV2FPT0WU
Becker	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHm1N4lKSzVyPUGuOlQzPDFizszN	NH;HSWFUSU6JRWK=
OE19	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTFwNkW1NVgh\|ryP	NGK0d2JUSU6JRWK=
EKVX	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHITWM2OD1zLk[1OlE5KM7:TR?=	NGTUVINUSU6JRWK=
KLE	M3SxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjWSnVKSzVyPUGuOlU4OTRizszN	MVHTRW5ITVJ?
K-562	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3hSm1KSzVyPUGuOlcxOzdizszN	NU[zU5dIW0GQR1XS
MDA-MB-175-VII	MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1:zZWlEPTB;MT62PFk6PyEQvF2=	MYPTRW5ITVJ?
NCI-H716	MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\sTWM2OD1zLk[5N\|A1KM7:TR?=	MXTTRW5ITVJ?
Caov-3	NUX0S5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlX1TWM2OD1zLk[5OFE{KM7:TR?=	NHHZVZNUSU6JRWK=
HCC1187	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEny[HBKSzVyPUGuO\|A2PDVizszN	NUj4V2p7W0GQR1XS
CAKI-1	NGThfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3sWo9KSzVyPUGuO\|IzQTJizszN	NYTQSWlZW0GQR1XS
MOLT-16	M{O2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTFwN{OzNFch\|ryP	NYmybI97W0GQR1XS
PC-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DsNWlEPTB;MT63OVA5KM7:TR?=	M3zmXHNCVkeHUh?=
DV-90	NXGxcnJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTFwN{W1PFUh\|ryP	MXLTRW5ITVJ?
RXF393	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfZVXdKSzVyPUGuO\|czQTRizszN	MUTTRW5ITVJ?
SK-NEP-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjYTWM2OD1zLkiyN\|M6KM7:TR?=	MVTTRW5ITVJ?
HCC1419	NFX5c2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTqTWM2OD1zLkiyOlkzKM7:TR?=	NXLhfW5qW0GQR1XS
BV-173	NHf4RVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXL6cGFEUUN3ME2xMlgzQTl3IN88US=>	NX\ZZVh5W0GQR1XS
MKN7	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWmySppOUUN3ME2xMlg6OjJizszN	MkjwV2FPT0WU
LAN-6	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\qcGlEPTB;MT64PVU2OyEQvF2=	NELoe3RUSU6JRWK=
Mo-T	NIj0N4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHq2TWtKSzVyPUGuPVAxOzlizszN	NEPTN5FUSU6JRWK=
HCC1395	NU\4OYVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7XSIlxUUN3ME2xMlkzQDZ\|IN88US=>	MXnTRW5ITVJ?
HC-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELMWoJKSzVyPUGuPVM1PyEQvF2=	MljHV2FPT0WU
HPAF-II	M4DlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;hbWlEPTB;MT65OFQyQCEQvF2=	NV[2fGRzW0GQR1XS
CPC-N	NULldnN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTFwOUiwNFIh\|ryP	M4D3bHNCVkeHUh?=
MKN45	NGXUZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7XSXFKSzVyPUGuPVkyOTlizszN	MknoV2FPT0WU
NCI-H1693	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHEb\|dKSzVyPUKuNFA1OzNizszN	MlXtV2FPT0WU
SHP-77	NFfGVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYSycYZGUUN3ME2yMlAxPTN\|IN88US=>	MnW3V2FPT0WU
NCI-H1522	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDXTIRKSzVyPUKuNFE4OjRizszN	NVOwNXdxW0GQR1XS
SW1573	NG\hemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTITWM2OD1{LkCyNkDPxE1?	NXL2eoNmW0GQR1XS
DBTRG-05MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDwcIh[UUN3ME2yMlA3ODh5IN88US=>	MYrTRW5ITVJ?
SCC-4	MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTINZQ4UUN3ME2yMlE1OzFizszN	NU\kcZBNW0GQR1XS
DMS-153	M4LL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXV[mFKSzVyPUKuNVY3PjhizszN	NV\CVo5xW0GQR1XS
MDA-MB-415	NV\2UWJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHlTWM2OD1{LkG3OVIh\|ryP	MlPwV2FPT0WU
NCI-H2126	M1WyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TEOWlEPTB;Mj6yNlg5QCEQvF2=	NHvI[pZUSU6JRWK=
MDA-MB-453	M4jLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3PRo9KSzVyPUKuNlM{OiEQvF2=	MYnTRW5ITVJ?
U-87-MG	MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTJwMki1PVIh\|ryP	M4XBNnNCVkeHUh?=
LNCaP-Clone-FGC	NG\DdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojlTWM2OD1{LkOwNVAzKM7:TR?=	MVfTRW5ITVJ?
NCI-H1581	NV:1XphQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDGNm5KSzVyPUKuN\|IyODVizszN	M4frRXNCVkeHUh?=
BC-3	NHXPOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1m1OGlEPTB;Mj6zOlUxQSEQvF2=	MUTTRW5ITVJ?
HCC38	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTJwM{i0OFch\|ryP	Ml;0V2FPT0WU
HCC2218	MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjWTWM2OD1{LkSwPFA6KM7:TR?=	MVjTRW5ITVJ?
RO82-W-1	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\O[FJKSzVyPUKuOFEzPSEQvF2=	NWW3Vmt4W0GQR1XS
C2BBe1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjMcWNKSzVyPUKuOFE2PzhizszN	NH6yUY9USU6JRWK=
LAMA-84	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnJUFVKSzVyPUKuOVc{PjhizszN	MkXxV2FPT0WU
GMS-10	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TJZ2lEPTB;Mj61O\|YyOSEQvF2=	NG\Be5ZUSU6JRWK=
GCT	NInM[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTJwNUi2PVQh\|ryP	MnXLV2FPT0WU
SK-CO-1	NXPJ[odUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHUTWM2OD1{Lk[xOlYh\|ryP	NUXyOVkxW0GQR1XS
NCI-H526	MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTJwNkO0OUDPxE1?	Mli3V2FPT0WU
SW1088	NFTke\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4q4RWlEPTB;Mj63O\|g{QSEQvF2=	MVvTRW5ITVJ?
HT55	MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTJwN{i2PVUh\|ryP	NWLsbZlkW0GQR1XS
NB10	M3e3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3m1UmlEPTB;Mj64NVc1QCEQvF2=	NYHzTGNMW0GQR1XS
UACC-893	NWTRW4VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjCTWM2OD1{Lki1O\|Q6KM7:TR?=	MUDTRW5ITVJ?
NCI-H1618	NGHNNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXoe21KSzVyPUKuPFgyPTNizszN	MnjPV2FPT0WU
NCI-H1092	MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPHNlBKSzVyPUOuNFc5OTJizszN	MV\TRW5ITVJ?
SBC-1	NFT1XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XwRmlEPTB;Mz6wPFU2OyEQvF2=	M2fCUXNCVkeHUh?=
NCI-H1623	NFewOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDLUIdjUUN3ME2zMlA6OzRizszN	MmLBV2FPT0WU
SiHa	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTNwMUG5O\|ch\|ryP	MXXTRW5ITVJ?
D-263MG	NFrBNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\pTWM2OD1\|LkG0O\|g5KM7:TR?=	NXrrNoVvW0GQR1XS
NCI-H1573	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3Sco9KSzVyPUOuNVk3PDFizszN	NXX1UnpiW0GQR1XS
NCI-H82	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvFUVlMUUN3ME2zMlM1PDN7IN88US=>	NGfrXWJUSU6JRWK=
NCI-H2196	NHTPfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PyO2lEPTB;Mz6zOVAxQCEQvF2=	M1e0Z3NCVkeHUh?=
MFM-223	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV74e2VwUUN3ME2zMlM4OzVzIN88US=>	M3LFb3NCVkeHUh?=
COLO-678	NWn2bHJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDiTWM2OD1\|LkO4NVg3KM7:TR?=	NX;HdllbW0GQR1XS
EW-3	NFnw[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEK2TpdKSzVyPUOuOFA6PSEQvF2=	NILYZWhUSU6JRWK=
MHH-NB-11	NUXRXGd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXjTWM2OD1\|LkS0NFY6KM7:TR?=	M{HzXHNCVkeHUh?=
EM-2	NUL1WIt{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfT[ZBCUUN3ME2zMlY{QThizszN	MYnTRW5ITVJ?
FTC-133	NGrSUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n4SGlEPTB;Mz62OVQ2QCEQvF2=	MWTTRW5ITVJ?
NCI-H209	MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDIWWRiUUN3ME2zMlY4PjV\|IN88US=>	NV:5O255W0GQR1XS
TGBC24TKB	NVHDSGtkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIL0OXNKSzVyPUOuOlg{PTVizszN	NV7GN2RHW0GQR1XS
LC-1F	M{T5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPIUXk1UUN3ME2zMlcyPzZ2IN88US=>	NITGTlVUSU6JRWK=
C-4-II	MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTNwN{W2OFMh\|ryP	NI\nb3dUSU6JRWK=
NCI-H1650	NUjWSpEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jD[WlEPTB;Mz63PFQ2PSEQvF2=	MWfTRW5ITVJ?
JVM-2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\6fIxNUUN3ME2zMlk{PjN7IN88US=>	NWH2VnBWW0GQR1XS
CaR-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfJblNKSzVyPUOuPVc3OTdizszN	M{XsOnNCVkeHUh?=
MDA-MB-134-VI	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjuRVZKSzVyPUSuNFI6PTJizszN	MofhV2FPT0WU
NCI-H719	NXrwTmV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfBTWM2OD12LkG1N\|g5KM7:TR?=	MXnTRW5ITVJ?
GOTO	M1X2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3POfWlEPTB;ND6yPVcxPSEQvF2=	MmW0V2FPT0WU
NCI-N87	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XLSmlEPTB;ND6zPFgzOSEQvF2=	M3\KdnNCVkeHUh?=
NB6	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTRwNEK1NFkh\|ryP	Mn[1V2FPT0WU
DSH1	NFfyRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXJTWM2OD12LkS3NVE3KM7:TR?=	MVrTRW5ITVJ?
BT-20	NX\yTpdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2OyXWlEPTB;ND60PVAxOiEQvF2=	MUTTRW5ITVJ?
NCI-H1882	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\KTWM2OD12LkWwOVch\|ryP	MmnjV2FPT0WU
WM-115	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfjV\|dKSzVyPUSuOVA5QDFizszN	NFjZS3FUSU6JRWK=
SKG-IIIa	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fSXGlEPTB;ND62O\|c4KM7:TR?=	M{WzWnNCVkeHUh?=
NCI-H69	M2XIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDqTWM2OD12LkewNlc2KM7:TR?=	NU\Kb\|ZzW0GQR1XS
MSTO-211H	M{DsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUe1Nmk6UUN3ME20Mlg{PTZ3IN88US=>	NYq3UnVYW0GQR1XS
Mewo	NG\YZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXGTWM2OD12Lkm2N\|E{KM7:TR?=	MoPoV2FPT0WU
GI-ME-N	NUXYblJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkP5TWM2OD13LkCwOVA6KM7:TR?=	MkGzV2FPT0WU
T98G	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvqWW5KSzVyPUWuNFY2ODhizszN	NVTheWY5W0GQR1XS
ECC4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{ew[2lEPTB;NT6wPVM4OiEQvF2=	MUPTRW5ITVJ?
EW-11	M1f2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnY[25KSzVyPUWuNVgxQTlizszN	NYSxeZNOW0GQR1XS
COLO-800	NV7iWnpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPFe3VKSzVyPUWuNVk{PDlizszN	MU\TRW5ITVJ?
NCI-H1755	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTVwMkOwNlch\|ryP	MkDiV2FPT0WU
KMS-12-PE	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTPfG5KSzVyPUWuN\|UxQDVizszN	NIDmOW1USU6JRWK=
HCC1954	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPQVVNKSzVyPUWuPFU6PzFizszN	NXf3U2IyW0GQR1XS
NCI-H187	M1PNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHM[IR6UUN3ME21MlkzQTh7IN88US=>	MVvTRW5ITVJ?
LU-165	M{DqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;ETWM2OD13Lkm5NFAzKM7:TR?=	MWTTRW5ITVJ?
YAPC	NWLpcpl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7NdFlKSzVyPUWuPVkxPjhizszN	M13iVnNCVkeHUh?=
LU-139	MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLTd\|dkUUN3ME22MlA5OzZ6IN88US=>	MX3TRW5ITVJ?
D-502MG	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTZwM{KwOFch\|ryP	NXLydXNLW0GQR1XS
IST-SL1	M2Dhe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\4bZZKSzVyPU[uOVM6PDhizszN	NVrxNmYzW0GQR1XS
DG-75	NUXwe3dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLhSohbUUN3ME22Mlg5Pzh4IN88US=>	M1n2UnNCVkeHUh?=
NCI-H1155	Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HSRWlEPTB;Nj65OVU5OSEQvF2=	NGfD[WtUSU6JRWK=
EFE-184	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zjUWlEPTB;Nz6zNVY6PSEQvF2=	NYTy[VNlW0GQR1XS
AsPC-1	NXvEcm0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XDW2lEPTB;Nz60PFgxPyEQvF2=	MYTTRW5ITVJ?
SW948	NYr3WJNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\GUmlKSzVyPUeuOVg{QTVizszN	MmPKV2FPT0WU
NCI-H524	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:0VmdVUUN3ME25MlU5PjJ6IN88US=>	NGPI[IhUSU6JRWK=
KOSC-2	M2PIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\YSpR[UUN3ME25MlYzQDN2IN88US=>	NVPKUIVrW0GQR1XS
T-24	NXvIPW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPNTWM2OD17Lkm0OFE2KM7:TR?=	Ml;qV2FPT0WU
NCI-H748	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXUb5JKSzVyPUGwMlY{QTdizszN	MX;TRW5ITVJ?
NCI-H23	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PkR2lEPTB;MUCuOlQ1OiEQvF2=	NHfTe4FUSU6JRWK=
UACC-812	M2PBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrmOVJKSzVyPUGxMlcyPyEQvF2=	NGX4OHNUSU6JRWK=
SCLC-21H	NGfyfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLCTZBKSzVyPUGyMlE2PTFizszN	Mk[wV2FPT0WU
NCI-SNU-16	NGHydmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTF\|LkGyOVgh\|ryP	M1f2OnNCVkeHUh?=
HD-MY-Z	NU\Oc3ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;tNXdKSzVyPUG0MlY{PjNizszN	NVv5WnZMW0GQR1XS
SK-N-FI	M2fP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HDVWlEPTB;MUSuPFkyOiEQvF2=	NIe2WFBUSU6JRWK=
LB647-SCLC	Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;YTGlEPTB;MUWuO\|E6PSEQvF2=	M4XP[XNCVkeHUh?=
NCI-H345	NWTNU5B[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLaTWM2OD1zNz6zOFMh\|ryP	MnHyV2FPT0WU
NCI-H1563	NV7RNZJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\RNGhTUUN3ME2xPE44PjBzIN88US=>	NVzTVFFwW0GQR1XS
RL	NHrlSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPrNYtOUUN3ME2yNU4zPjV4IN88US=>	Ml3GV2FPT0WU
KY821	M{fuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTJ{LkC1OVMh\|ryP	NWT1fZdIW0GQR1XS
JVM-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fIbGlEPTB;MkWuNFQyOyEQvF2=	NXXnVJBbW0GQR1XS
NCI-H1793	NICz[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzycnpKSzVyPUK4MlU1QTlizszN	NF35dG9USU6JRWK=
LU-134-A	MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXqTWM2OD1\|MD6yNFM4KM7:TR?=	MnXFV2FPT0WU
NCI-H1395	Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlGwTWM2OD1\|Mj6yOFMyKM7:TR?=	NEL1PFdUSU6JRWK=
NCI-H1993	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDmd3llUUN3ME2zNk45OjF6IN88US=>	MULTRW5ITVJ?
P31-FUJ	NV3XNYluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoWyTWM2OD1\|Mz60PFk6KM7:TR?=	NWPOPJIyW0GQR1XS
LS-513	NFyy[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTN3Lki4O\|kh\|ryP	M3i3fnNCVkeHUh?=
SK-MEL-1	MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1O2TWlEPTB;NECuN\|Q6QSEQvF2=	M2Tqe3NCVkeHUh?=
SW684	NIHDdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTR\|Lkm2OlEh\|ryP	NH3LcmxUSU6JRWK=
COR-L88	NV\Ud\|U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTR2LkC2OlUh\|ryP	M4C4W3NCVkeHUh?=
NCI-H889	NHm5WHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlH2TWM2OD12NT6wNFg4KM7:TR?=	NGPBelhUSU6JRWK=
TALL-1	Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILnV5VKSzVyPUS2MlEyQTlizszN	MmrmV2FPT0WU
KARPAS-299	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTR5LkG5PVMh\|ryP	M2XwXHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cyclin D1 / p27 Kip1 ; PubMed: 28382170 Theranostics Western blotting showed that Obatoclax impacted cell cycle distribution through lowering cyclin D1 in K1 cells but in BCPAP cells, it impacted expression of p27 Kip1 rather than cyclin D1. p-Cyclin D1 ; PubMed: 28035994 Int J Mol Sci Cell line-dependent effect of obatoclax on cyclin D1 T286 phosphorylation. HCT116, HT-29, and LoVo cells were subject to 24 h-treatment with obatoclax (200 nM), followed by immunoblotting to evaluate the levels of threonine 286 (T286)-phosphorylated cyclin D1 (p-Cyclin D1) at indicated time points. α-Tubulin levels served as equal loading control; p-GSK3β / GSK3β / p-ERK / ERK / p-p38 / p38; PubMed: 28035994 Int J Mol Sci Obatoclax inhibits GSK3β but activates p38 (MAPK), while barely affecting ERK1/2 activity in HT-29 cells. HT-29 cells were exposed to 200 nM of obatoclax for 24 h. The status of activation of GSK3β, ERK1/2, and p38(MAPK) at indicated time points was determined by immunoblotting for corresponding phosphorylation. Specifically, serine 9-phosphorylation of GSK3β (p-GSK3β) reveals inhibition of GSK3β activity, whereas dual phosphorylation at threonine 202/tyrosine 204 of ERK1/2 (p-ERK1/2) and threonine 180/tyrosine 182 of p38 MAPK (p-p38) indicate activation of ERK1/2 and p38(MAPK), respectively. α-Tubulin levels served as equal loading control;	28382170 28035994
Growth inhibition assay	Cell proliferation ; PubMed: 28035994 Int J Mol Sci Obatoclax inhibits colorectal cancer cell proliferation. Human colorectal carcinoma cell lines HCT116, HT-29, and LoVo cells were treated with obatoclax (0, 50, 100, 200 nM) for 24, 48, and 72 h. The numbers of cells at each time point were counted using a Neubauer chamber. Data were presented as the percentage relative to the drug-untreated control. Cell viability; PubMed: 21368880 Cell Death Dis H727 NSCLC cells are resistant to obatoclax. H727 and H1975 NSCLC cells were treated with obatoclax at the indicated doses for 48 (left) or 72 h (right), and the viability of cells determined by ViaLight assay. The EC50 values of cells at 48 h were; H1975 267 nM; H727 3.2 μM. The EC50 values of cells at 72 h were; H1975 66 nM; H727 621 nM. Data are expressed as mean±S.D.	28035994 21368880

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	- Collapse Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

- Collapse

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	COC\1=CC(=NC1=C\C2=C(C)C=C(C)[NH]2)C3=CC4=CC=CC=C4[NH]3.C[S](O)(=O)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00438178	Completed	Drug: Obatoclax mesylate (GX15-070MS)	Hematological Malignancies	Gemin X\|Teva Pharmaceutical Industries	October 2005	Phase 1
NCT00600964	Completed	Drug: GX15-070MS	Chronic Lymphocytic Leukemia	Gemin X\|Teva Pharmaceutical Industries	September 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)